8-KLeadership ChangesShareholder MattersExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Oct 23, 2023)

Filed October 23, 2023For Securities:MDT

Summary

This 8-K filing from Medtronic plc details the outcomes of their 2023 Annual General Meeting of Shareholders held on October 19, 2023. The most significant news for investors is the shareholder approval of the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan). This new plan will replace the existing 2014 Plan and makes available 30 million ordinary shares, with the first purchase period commencing January 1, 2024. Additionally, all director nominees were elected, the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024 was ratified, and executive compensation was approved on an advisory basis. The company also secured shareholder approval for the renewal of the Board's authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of its shares, which are important for strategic financial flexibility.

Key Highlights

  • 1Shareholders overwhelmingly approved the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan), which makes 30 million ordinary shares available.
  • 2The 2024 Plan will commence with its first purchase period on January 1, 2024, and effectively replaces the Medtronic plc 2014 Amended and Restated Employees Stock Purchase Plan.
  • 3All eleven director nominees were elected to the Board of Directors, ensuring continuity in leadership.
  • 4PricewaterhouseCoopers LLP was ratified as Medtronic's independent auditor for fiscal year 2024 through a non-binding vote.
  • 5Shareholders provided advisory approval for the compensation of the company's named executive officers.
  • 6The Board of Directors' authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of Medtronic ordinary shares was renewed, providing strategic and financial flexibility.

Frequently Asked Questions

The 2024 Plan, approved by shareholders, will provide employees with an opportunity to purchase Medtronic ordinary shares at a discount. It makes 30 million shares available and begins on January 1, 2024, replacing the current 2014 Plan. This initiative is a common way for companies to incentivize and retain employees by aligning their interests with shareholders.

Yes, in addition to the stock purchase plan, shareholders elected all director nominees, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for FY24, and approved executive compensation on an advisory basis. Furthermore, the board's authorities for issuing shares, opting out of pre-emption rights, and conducting overseas share repurchases were renewed.

The Medtronic plc 2014 Amended and Restated Employees Stock Purchase Plan (2014 Plan) will be terminated. It will cease to allow new purchase periods after December 31, 2023, and will be fully terminated after the final issuance of shares to employees for the purchase period ending December 31, 2023.

This specific 8-K filing pertains to the outcomes of the Annual General Meeting and the approval of governance-related items and employee plans. It does not contain financial statements or management's discussion and analysis of financial condition or results of operations, which are typically found in quarterly (10-Q) or annual (10-K) reports. Therefore, this filing does not directly provide insights into Medtronic's current financial performance or outlook.